课题基金 / 基金详情

项目摘要

项目成果

Stephan Zuchner的其他基金

相似基金

相关文献

中文摘要
翻译
超过70种不同的基因已被确定导致各种形式的CMT。对于脱髓鞘形式的CMT,大多数情况下可以发现遗传原因,CMT1A (PMP22重复)解释了约70%的这些病例。相比之下,在不到40%的轴突(CMT2)病例中可以发现目前已知基因中的一个突变,主要是在严重的早期发病病例中。基因研究从根本上改变了我们对CMT的认识,并在过去的20年里催化了许多神经疾病的研究。我们完全期望,通过利用新技术,这一进展将继续下去,达到(1)100 - 90%的CMT1和CMT2患者可以接受基因诊断;(2)将确定相当数量的重要遗传修饰因子,这些修饰因子在某些形式的CMT中占显型变异性的重要部分;(3)迄今为止,一定比例的特发性/散发性神经病将被发现有遗传原因;(4)确定神经病变发展为糖尿病的遗传危险因素和各种药物。
英文摘要
More than 70 different genes have been identified to cause the various forms of CMT. For the demyelinating forms of CMT, a genetic cause can be found most of the time, with CMT1A (PMP22 duplication) explaining ~70% of these cases. In contrast, a mutation in one of the currently known genes can be found in less than 40% of axonal (CMT2) cases, mostly for the severe, early onset cases. Genetic studies have fundamentally transformed our knowledge on CMT and have catalyzed much of the research in neuropathies in the past 20 years. We fully expect that by taking advantage of new technologies, this progress will continue to a point where (1) >90% of CMT1 and CMT2 patients can receive a genetic diagnosis; (2) a sizable number of important genetic modifiers that account for a significant portion of the phenotypic variability in some forms of CMT will be identified; (3) a proportion of the heretofore idiopathic/sporadic neuropathies will be found to have a genetic cause; (4) genetic risk factors for developing neuropathy to diabetes and various medications will be identified. The members of the INC consortium work in a collaborative manner with multiple sources of funding to achieve these goals. In particular, the INC has allowed us to collect high-quality samples for reliable gene modifier studies, as demonstrated by our results on a CMT1A study. In this renewal, we propose to expand our efforts to find new genes that cause CMT and genetic modifiers of CMT. These modifiers will be important targets for intervention, and may well be important in the manifestations of acquired peripheral neuropathies, and even other diseases, such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis, in which axonal degeneration has been implicated in the pathogenesis. Finally, as our collaborative group and others move rapidly towards genomic approaches, we will establish a unified, secure, and accessible resource for all genomic data of the INC that will be open to all CMT researchers, that can also serve as a blueprint for other RDCRN groups interested in inherited diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genome Studies in Hereditary Spastic Paraplegia
Genome Studies in Hereditary Spastic Paraplegia
Genome Studies in Hereditary Spastic Paraplegia
Genome Studies in Hereditary Spastic Paraplegia
海外基金